Biohaven to present FGFR3 ADC trial data at ENA2026: Will BHVN hold $13.6 support?

Biohaven to present FGFR3 ADC trial data at ENA2026: Will BHVN hold $13.6 support?
Biohaven stock is little changed today

Biohaven is preparing to present data from its ongoing Phase 1 trial of an investigational FGFR3-directed ADC during a plenary session at ENA2026 in Barcelona. The stock is little changed on the day, trading near $13.8.

Highlights

  • Biohaven will present Phase 1 data for its investigational FGFR3-directed ADC and display its TopoIx ADC platform at ENA2026 in Barcelona.
  • 50 of 68 analysts rate Biohaven stock a buy, with a median price target of $20 nearly 44.9% above current levels.
  • Shares of Biohaven are little changed on the day, trading near $13.8.

Biohaven is set to attend ENA2026 in Barcelona. The company will present new data from the ongoing Phase 1 trial of its investigational FGFR3-directed ADC in a plenary oral presentation. In addition, Biohaven will showcase its proprietary TopoIx ADC platform.

Short-term support as oversold Stoch RSI meets split chart structure

Stoch RSI is in oversold territory, offering some support against further downside in shares of Biohaven. The price is currently positioned below the MA-20 but remains above the MA-50 and MA-200, reflecting a split daily chart structure. The nearest support sits at the Ichimoku Kijun at $13.6, helping to anchor short-term price action.

Odds tilt to the downside as scope for further losses remains limited

A move above $14.54 would indicate growing buyer interest and confirm that the event is being priced in, while a drop below $13.6 would suggest the move is being rejected. With Stoch RSI stretched in oversold territory, scope for additional losses is limited and may foster near-term stabilization. Even so, after a sharp move lower over the past week without a sustained trend, the probability for downside is 59% and upside is 41% over the next five trading days, with an expected trading range between $12.88 and $14.71. On the weekly chart the longer-term picture stays mixed.

Previously it was reported that Biohaven's outlook turned bullish following a collaboration deal, as technical indicators pointed to upside potential. With the stock now consolidating near support ahead of key trial data at ENA2026, the prevailing scenario suggests a mixed but potentially stabilizing range, with $13.6 emerging as a critical level to monitor for directional cues.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.